Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 12/20 | 0.52 |
| ▸ | NOS1 | P29475 | 7/20 | 0.52 |
| ▸ | NOS3 | P29474 | 5/20 | 0.52 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053563 | 0.87 | NOS3 (0.46) | NOS2NOS1NOS3KDM4EPDK1 | |
| SCHEMBL3064877 | 0.84 | NOS2 (0.53) | NOS2NOS1NOS3KDM4EPDK1 | |
| SCHEMBL3043358 | 0.83 | NOS2 (0.56) | NOS2NOS1NOS3GPBAR1NR1H4 | |
| SCHEMBL3058609 | 0.81 | NOS1 (0.51) | NOS2NOS1NOS3GPBAR1KDM4E | |
| SCHEMBL3057645 | 0.81 | NOS3 (0.47) | NOS2NOS1NOS3GPBAR1NR1H4 | |
| SCHEMBL3064357 | 0.79 | NOS2 (0.46) | NOS2NOS1NOS3KDM4E | |
| SCHEMBL3053787 | 0.77 | NOS2 (0.48) | NOS2NOS1NOS3GPBAR1KDM4E | |
| SCHEMBL3061243 | 0.77 | NOS2 (0.49) | NOS2NOS1NOS3GPBAR1KDM4E | |
| SCHEMBL3061893 | 0.72 | GPBAR1 (0.49) | NOS2NOS1NOS3GPBAR1NR1H4 | |
| SCHEMBL3058776 | 0.70 | NOS2 (0.53) | NOS2NOS1NOS3GPBAR1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| EP-2001851-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | NOS2 3548/4885NOS1 3682/4885NOS3 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.